Gilead goes all in on its Ar­cus al­liance, pay­ing $725M cash for rights to a slate of can­cer drugs. And there's no room for fail­ure

Gilead is go­ing all in — hook, line and sinker — on its on­col­o­gy al­liance with Ar­cus. And they are go­ing for broke.

The big biotech un­veiled a deal that now de­liv­ers $725 mil­lion in opt-in pay­ments cov­er­ing the clin­i­cal de­vel­op­ment pro­grams for Ar­cus, rang­ing from their close­ly watched an­ti-TIG­IT pro­grams for dom­vanal­imab and AB308 to etru­madenant (the A2a/A2b adeno­sine re­cep­tor an­tag­o­nist) and quem­li­clu­s­tat, the small mol­e­cule CD73 in­hibitor. Gilead will al­so cov­er half of the de­vel­op­ment costs, hand­ing Ter­ry Rosen’s biotech a deal that gives them a clear cash run­way to achiev­ing all its goals in on­col­o­gy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER